Daiichi Sankyo

Daiichi Sankyo Co., Ltd.
Company type	Public KK (TYO: 4568)
Industry	Pharmaceutical
Founded	2005 (by merger)
Headquarters	Tokyo, Japan
Key people	Kiyoshi Morita, Chairman; Takashi Shoda, President & CEO
Revenue	¥ 880,120 million JPY (FY 2007)
Net income	¥ 97,660 million JPY (FY 2007)
Number of employees	30,000 (2010) products = Pharmaceutical products
Website	www.daiichisankyo.com

Daiichi Sankyo Co., Ltd. (第一三共株式会社, Daiichi Sankyō Kabushiki-kaisha, TYO: 4568) is a Japan-based major pharmaceutical company, which ranks number 20 in the world in sales^[1].

History

Daiichi Sankyo was established in 2005 through the merger of Sankyo Co., Ltd. (三共株式会社, Sankyō Kabushiki Kaisha) and Daiichi Pharmaceutical Co., Ltd. (第一製薬株式会社, Daiichi Seiyaku Kabushiki Kaisha), which were century-old pharmaceutical companies based in Japan.

Acquisitions

In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.

On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO after the transaction.^[2]^[3]

In June 2008, the company expressed intent to acquire U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.^[4]

On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, the Berkley CA based, venture-backed small molecule pharmaceutic start-up for $805 and an additional $130 in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (GSK licensed) drug. ^[5]

Products of Daiichi Sankyo Group

Sankyo

Benicar (olmesartan medoxomil)
Mevalotin (pravastatin)
Loxonin (loxoprofen)
Olmetec (olmesartan)
Captopril
WelChol (colesevelam HCl)
Effient (Prasugrel)

win bp piramal (olmesartan medoxomil)

Panipenem

Daiichi Pharmaceutical

Cravit (levofloxacin)
Evoxac (cevimeline)
FloxinOtic (ofloxacin)
Gracevit (sitafloxacin, only sold in Japan)

Pipeline candidates

Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include:

CS-011 (rivoglitazone)—Type 2 Diabetes
CS-1008—Oncology
CS-8958 (Laninamivir)—Influenza
DU-176b—Venous thromboembolism
SUN-11031—Cachexia

References

^ http://pharmexec.findpharma.com/pharmexec/data/articlestandard//pharmexec/302008/531367/article.pdf
^ Daiichi to get 35% stake in Ranbaxy
^ The Brand Blog: Ranbaxy promoters to sell stake to Japan's Daiichi
^ staff (2008-06-15). Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. p. 8. {{cite news}}: |access-date= requires |url= (help); Missing or empty |title= (help)
^ "Daiichi Sankyo To Acquire Plexxiko".

Daiichi Sankyo Annual Report 2008

External links

This article about a Japanese corporation- or company-related topic is a stub. You can help Wikipedia by expanding it.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

[1] ttp://pharmexec.findpharma.com/pharmexec/data/articlestandard//pharmexec/302008/531367/article.pdf

[2] Daiichi to get 35% stake in Ranbaxy

[3] The Brand Blog: Ranbaxy promoters to sell stake to Japan's Daiichi

[4] staff (2008-06-15). Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. p. 8. {{cite news}}: |access-date= requires |url= (help); Missing or empty |title= (help)

[5] "Daiichi Sankyo To Acquire Plexxiko".

[1]

[2]

[3]

[4]

[5]